EGFR and myosin II inhibitors cooperate to suppress EGFR‐T790M‐mutant NSCLC cells

An acquired mutation (T790M) in the epidermal growth factor receptor (EGFR) accounts for half of all relapses in non‐small cell lung cancer (NSCLC) patients who initially respond to EGFR kinase inhibitors. In this study, we demonstrated for the first time that EGFR‐T790M interacts with the cytoskele...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Oncol
Autors principals: Chiu, Huan-Chih, Chang, Teng-Yuan, Huang, Chin-Ting, Chao, Yu-Sheng, Hsu, John T.-A.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2012
Matèries:
Papers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528336/
https://ncbi.nlm.nih.gov/pubmed/22366308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2012.02.001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars